Treatment
Cell clinical trials
We’re tracking 5,545 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07187778RecruitingPhase 2
Kidney cancer treatment before surgery
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
Houston, TexasAges 18 years+ - NCT07172958RecruitingPhase 1
Immune cell therapy for children with certain solid tumors
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
Washington D.C., District of ColumbiaAges 1–23 - NCT07164560RecruitingPhase 1
CAR-NK cell therapy for relapsed T-cell lymphoma
This trial tests a new treatment using immune cells (CAR-NK) made from donated cord blood. These cells are designed to find and attack T-cell lymphoma that has come back or not responded to other treatments. The goal is to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT07155200RecruitingPhase 1/Phase 2
Study of a new drug combined with irinotecan for small cell lung cancer
This study tests a new drug (cirtuvivint) combined with irinotecan, a common chemotherapy, for people whose small cell lung cancer has progressed after at least one prior treatment. The goal is to see if the combination helps control the cancer and whether it is safe.
St Louis, MissouriAges 18 years+ - NCT07145450RecruitingPhase 1/Phase 2
T-cell therapy for advanced pancreatic cancer with KRAS mutations
This trial tests a personalized T-cell therapy designed to target pancreatic cancer cells that have a specific KRAS mutation (G12V or G12D). It is for people whose cancer has spread or is locally advanced and who have already benefited from standard treatments.
CopenhagenAges 18 years+ - NCT07135466RecruitingPhase 1/Phase 2
Anti-CD22 CAR T-cell therapy for B-cell blood cancers
This trial tests a new treatment using your own immune cells (T-cells) that are modified to find and attack cancer cells with a marker called CD22. It is for people with B-cell blood cancers that have come back or not responded to at least two prior treatments, including a type of immunotherapy called CAR T-cell therapy.
Ramat Gan, GAges 1–80 - NCT07116057RecruitingPhase 1
CAR T cell therapy for FRa-positive cancers
This trial tests a new treatment called MOv19-BBz CAR T cells, which are specially designed immune cells that target a protein called FRa found on some cancer cells. It's for people with advanced lung cancer that has spread to the lining of the lung (malignant pleural effusion) and who have already tried at least one standard treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07107165Recruiting
Support for stem cell transplant patients and caregivers
This study tests a program to help stem cell transplant patients and their family caregivers cope with the stress of treatment. If you are getting a stem cell transplant at the University of Pittsburgh and have a caregiver who can join, you may be able to take part.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07101900Enrolling by invitationPhase 2
Better imaging for kidney cancer before surgery
This trial tests a new PET/CT scan that uses a special tracer to find clear cell kidney cancer. If you are scheduled for kidney tumor removal, this scan may help your surgeon see the cancer more clearly before surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
Duarte, CaliforniaAges 18 years+ - NCT06972576RecruitingPhase 1
EphA2-targeted CAR-DC and CAR-T cell therapy for advanced lung cancer
This trial tests a new combination therapy using your own immune cells (CAR-T and CAR-DC) that are specially trained to attack a protein called EphA2 found on your lung cancer cells. It is for people with advanced non-small cell lung cancer whose cancer has continued to grow after other treatments.
Hangzhou, ZhejiangAges 18–70 - NCT07085559RecruitingEarly Phase 1
Metabolically armed BCMA CAR-T for relapsed plasma cell cancer
This trial tests a new type of CAR-T cell therapy (Meta10-BCMA) that is "metabolically armed" to better fight cancer cells. It's for people with plasma cell cancers that have come back or not responded to multiple prior treatments, and whose cancer cells carry the BCMA protein.
Hefei, AnhuiAges 19–75 - NCT07083531Recruiting
Bone health study for older Black women with sickle cell trait
This study looks at how carrying the sickle cell trait (not the disease) affects bone density, physical function, and frailty in older African American women. It aims to help understand bone loss risk and prevent fractures.
Farmington, ConnecticutAges 50 years+ - NCT07073833RecruitingPhase 1
IBR900 cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07072234RecruitingPhase 1
CAR NK cell therapy for advanced clear cell kidney cancer
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
Houston, TexasAges 18 years+ - NCT07067905RecruitingEarly Phase 1
PET scan test for glioblastoma and kidney cancer
This trial tests a new PET scan tracer called [68Ga]Ga-XT771 to see if it can better detect glioblastoma (a type of brain tumor) and clear cell renal cell carcinoma (a type of kidney cancer). If you have one of these cancers, this scan might help your doctor see the tumor more clearly.
BeijingAges 18 years+ - NCT07052370RecruitingPhase 1
New stem cell transplant for children with high-risk blood cancer
This trial tests a special stem cell transplant from a half-matched family donor, designed to reduce rejection and infection risk. It may include a targeted drug (blinatumomab) to help kill remaining cancer cells.
Memphis, TennesseeAges Up to 21 years - NCT07044050RecruitingPhase 1
Study of OT-C001 natural killer cells for large B cell lymphoma
This trial tests a new treatment made from specially activated natural killer cells from a donor. It is for people with diffuse large B cell lymphoma that has come back or not responded to other treatments, including CAR T-cell therapy.
MontpellierAges 18 years+ - NCT06823479RecruitingPhase 2
Ultra-short immunotherapy before surgery for skin cancer
This trial tests a very short course of immunotherapy (nivolumab) before standard surgery for patients with certain types of advanced or hard-to-treat skin cancer (cutaneous squamous cell carcinoma). The goal is to see if this approach can reduce the need for extensive or disfiguring surgery.
Maastricht, LimburgAges 18 years+ - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT07009002RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed B-cell lymphoma
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
Beijing, Beijing MunicipalityAges 18–70 - NCT06988059RecruitingEarly Phase 1
Car T-cell therapy for plasma cell leukemia
This trial tests a new Car T-cell treatment called CT0596 for patients with plasma cell leukemia, a rare and aggressive blood cancer. It aims to see if this therapy can help control the disease in patients who have already tried other treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06980116RecruitingPhase 1
Finding the right dose of EXS73565 for relapsed B-cell cancers
This study tests a new oral medication (EXS73565) for people with B-cell blood cancers that came back or didn't respond to standard treatments. It aims to find the best dose and check if it's safe and helpful.
TbilisiAges 18 years+ - NCT06976229RecruitingPhase 1
Stem cell therapy for recent spinal cord injury
This phase 1 trial tests a new treatment made from stem cells (XS228) for people who had a spinal cord injury 14 to 60 days ago. Doctors want to see if it's safe and if it might help with recovery.
Guangzhou, GuangdongAges 18–65
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,545 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.